NASDAQ:VBIV

VBI Vaccines Stock Forecast, Price & News

$3.31
+0.10 (+3.12 %)
(As of 09/17/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.15
$3.33
50-Day Range
$2.80
$3.72
52-Week Range
$2.07
$4.83
Volume4.63 million shs
Average Volume4.38 million shs
Market Capitalization$847.39 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04
30 days | 90 days | 365 days | Advanced Chart
Receive VBIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.


VBI Vaccines logo

About VBI Vaccines

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

377th out of 1,350 stocks

Pharmaceutical Preparations Industry

186th out of 664 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions

Is VBI Vaccines a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VBI Vaccines stock.
View analyst ratings for VBI Vaccines
or view top-rated stocks.

What stocks does MarketBeat like better than VBI Vaccines?

Wall Street analysts have given VBI Vaccines a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VBI Vaccines wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is VBI Vaccines' next earnings date?

VBI Vaccines is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for VBI Vaccines
.

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc. (NASDAQ:VBIV) issued its quarterly earnings results on Sunday, August, 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.07). VBI Vaccines had a negative net margin of 7,014.58% and a negative trailing twelve-month return on equity of 37.04%.
View VBI Vaccines' earnings history
.

How has VBI Vaccines' stock price been impacted by Coronavirus (COVID-19)?

VBI Vaccines' stock was trading at $0.9171 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VBIV shares have increased by 260.9% and is now trading at $3.31.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for VBIV?

2 analysts have issued twelve-month price targets for VBI Vaccines' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate VBI Vaccines' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 111.5% from the stock's current price.
View analysts' price targets for VBI Vaccines
or view top-rated stocks among Wall Street analysts.

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the following people:
  • Jeff Baxter, President, Chief Executive Officer & Director
  • Christopher McNulty, CFO, Director & Head-Business Development
  • Francisco Diaz-Mitoma, Chief Medical Officer
  • David Evander Anderson, Chief Scientific Officer
  • T. Adam Buckley, Vice President-Business Development

Who are some of VBI Vaccines' key competitors?

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

Who are VBI Vaccines' major shareholders?

VBI Vaccines' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.03%), State Street Corp (4.94%), Vanguard Group Inc. (2.15%), Geode Capital Management LLC (1.43%), Northern Trust Corp (0.79%) and Cambridge Investment Research Advisors Inc. (0.76%). Company insiders that own VBI Vaccines stock include Christopher Mcnulty, Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc and Steven Gillis.
View institutional ownership trends for VBI Vaccines
.

Which major investors are selling VBI Vaccines stock?

VBIV stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., Rafferty Asset Management LLC, Citigroup Inc., Bank of America Corp DE, Susquehanna International Group LLP, Bank of New York Mellon Corp, and Wells Fargo & Company MN. Company insiders that have sold VBI Vaccines company stock in the last year include Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for VBI Vaccines
or view top insider-selling stocks.

Which major investors are buying VBI Vaccines stock?

VBIV stock was acquired by a variety of institutional investors in the last quarter, including Commonwealth Equity Services LLC, Millennium Management LLC, Group One Trading L.P., Geode Capital Management LLC, Cambridge Investment Research Advisors Inc., Squarepoint Ops LLC, Vanguard Group Inc., and Schonfeld Strategic Advisors LLC. Company insiders that have bought VBI Vaccines stock in the last two years include Christopher Mcnulty, Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc, and Steven Gillis.
View insider buying and selling activity for VBI Vaccines
or or view top insider-buying stocks.

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $3.31.

How much money does VBI Vaccines make?

VBI Vaccines has a market capitalization of $847.39 million and generates $1.06 million in revenue each year. The biopharmaceutical company earns $-46,230,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

How many employees does VBI Vaccines have?

VBI Vaccines employs 130 workers across the globe.

What is VBI Vaccines' official website?

The official website for VBI Vaccines is www.vbivaccines.com.

Where are VBI Vaccines' headquarters?

VBI Vaccines is headquartered at 222 Third Street Suite 2241, Cambridge MA, 02142.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at (617) 830-3031 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.